Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 6:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Transdermal Estrogen Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Aging and Estrogen on Cortical Function

NCT01268046
View directory record Official record
Conditions
Memory Loss, Cognitive Changes, Postmenopausal Symptoms
Interventions
Estradiol oral capsule, transderman estrogen patch, trasdermal placebo patch, placebo oral capsule
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 80 Years · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Sep 24, 2026, 6:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Resveratrol and Acute Exercise on Endothelial Function in Postmenopausal Women

NCT02256540
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Climara, Placebo patch, Resveratrol, Placebo
Drug · Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Sep 24, 2026, 6:40 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Estrogen Variability and Irritability During the Menopause Transition

NCT05388656
View directory record Official record
Conditions
Menopause, Irritable Mood
Interventions
Estradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release, Placebo, Progesterone 200 mg
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 59 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 24, 2026, 6:40 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

The Effects of Aging and Estrogen on the Pituitary

NCT00386022
View directory record Official record
Conditions
Healthy
Interventions
GnRH, NAL-GLU GnRH antagonist, Estrogen patch
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 80 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 24, 2026, 6:40 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Estradiol and Fear Extinction in Anorexia Nervosa (AN)

NCT02792153
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Estradiol
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Sep 24, 2026, 6:40 AM EDT
Withdrawn Phase 4 Interventional

Oral Microdose Lupron Versus Luteal Estradiol Trial in Poor Responder In Vitro Fertilization (IVF) Patients

NCT00826839
View directory record Official record
Conditions
Infertility
Interventions
Oral contraceptive pill and microdose lupron, E2 patch/antagonist
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Sep 24, 2026, 6:40 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Perimenopausal Estrogen Replacement Therapy Study

NCT01308814
View directory record Official record
Conditions
Perimenopause, Menopause, Depression
Interventions
Estradiol, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Sep 24, 2026, 6:40 AM EDT
Completed Phase 3 Interventional

Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido

NCT00331123
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Transdermal System, Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
20 Years to 70 Years · Female only
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 24, 2026, 6:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of an Adhesive Overlay on the Delivery of Contraceptive Hormones From ORTHO EVRA® in Healthy Women

NCT01535820
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay, Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Sep 24, 2026, 6:40 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Kronos Early Estrogen Prevention Study (KEEPS)

NCT00154180
View directory record Official record
Conditions
Menopause, Arteriosclerosis
Interventions
Conjugated equine estrogens 0.45 mg/day, Transdermal estradiol, 50 mcg/day, Micronized progesterone, 200 mg/day x 12 d/month, CEE , progesterone, estradiol patch or placebo for each, CEE, progesterone, transdermal patch or the placebo
Drug
Lead sponsor
Kronos Longevity Research Institute
Other
Eligibility
42 Years to 58 Years · Female only
Enrollment
728 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2009 · Synced Sep 24, 2026, 6:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function

NCT03112226
View directory record Official record
Conditions
Cognitive Impairment, Estrogen Deficiency, Menopause, Endothelial Dysfunction, Vascular Stiffness
Interventions
GnRHant + E2, GnRHant + Placebo
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Aurora, Colorado • Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Sep 24, 2026, 6:40 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes

NCT00946192
View directory record Official record
Conditions
Exercise-related Amenorrhea
Interventions
Transdermal 17Beta-estradiol, progesterone, Ethinyl Estradiol + Desogestrel, Sham Comparator
Drug · Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 21 Years · Female only
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 24, 2026, 6:40 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of Orchiectomy and Age on Vascular and Metabolic Health in Older Versus Younger Transgender Women

NCT05195164
View directory record Official record
Conditions
Transgender, Gender Identity, Vascular Stiffness, Vascular Inflammation, Insulin Sensitivity, Blood Pressure, Lipid Disorder, Appetitive Behavior
Interventions
No intervention
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 24, 2026, 6:40 AM EDT
Recruiting Phase 4 Interventional

Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression

NCT06610305
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Transdermal estradiol, Progesterone, Transdermal placebo patch, placebo capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 24, 2026, 6:40 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism

NCT00837616
View directory record Official record
Conditions
Turner Syndrome, Hypogonadism, Premature Ovarian Failure
Interventions
17 B estradiol orally, 17 B estradiol
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 20 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
2
States / cities
Jacksonville, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Sep 24, 2026, 6:40 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Cyclic vs. Constant Estradiol: Regimens' Effects on Brain Health

NCT07831499
View directory record Official record
Conditions
Menopause, Healthy Adult, Brain, Postmenopausal
Interventions
Cyclic Estradiol, Continuous Estradiol
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
38 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 24, 2026, 6:40 AM EDT
Recruiting Phase 3 Interventional

Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea

NCT06533865
View directory record Official record
Conditions
FHA (Functional Hypothalamic Amenorrhea)
Interventions
Romosozumab, Placebo, Zoledronic acid
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 30 Years · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 24, 2026, 6:40 AM EDT
Not yet recruiting Phase 2 Interventional

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

NCT07466498
View directory record Official record
Conditions
Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan, Computed Tomography, Dual X-ray Absorptiometry, Gonadotropin-releasing Hormone Analog, Magnetic Resonance Imaging, Survey Administration, Biospecimen Collection
Drug · Procedure · Biological + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 24, 2026, 6:40 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Effect of Sex Steroid Replacement Therapy in the Hypogonadism and Transgender Active-Duty Population

NCT06247267
View directory record Official record
Conditions
Hypogonadism, Gender Identity Dysphoria
Interventions
Fortesta, Estradiol
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 24, 2026, 6:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Relationship Between the Menstrual Cycle and Heart Disease in Women

NCT01546454
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
Ethinyl Estradiol-Levonorgestrel combination, leuprolide acetate, Estradiol, Progesterone
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 24, 2026, 6:40 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of Reproductive Hormones on Mood and Behavior

NCT00001322
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Leuprolide Acetate 3.75, Estradiol, Progesterone, Placebo suppository, Placebo patch
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Sep 24, 2026, 6:40 AM EDT
Completed Phase 4 Interventional Results available

Raloxifene and Rimostil for Perimenopause-Related Depression

NCT00030147
View directory record Official record
Conditions
Perimenopausal Depression, Depression
Interventions
Raloxifene, Rimostil, Transdermal Estradiol, Placebo skin patch and placebo tablets
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
40 Years to 60 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2016 · Synced Sep 24, 2026, 6:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women

NCT00608062
View directory record Official record
Conditions
Arterial Stiffening, Aging, Menopause
Interventions
GnRHant - Ganirelix acetate, Transdermal estradiol patch, Transdermal placebo patch
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Sep 24, 2026, 6:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women

NCT03018366
View directory record Official record
Conditions
Estrogen Deficiency, Cardiovascular Disease (CVD), Functional Hypothalamic Amenorrhea, Endothelial Dysfunction
Interventions
17beta Estradiol, Transdermal placebo patch, Progesterone, Placebo Pill
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Sep 24, 2026, 6:40 AM EDT